Kyverna Therapeutics Gets FDA IND Clearance for KYV-101

By Chris Wack Kyverna Therapeutics said it has received clearance for its Investigational New Drug, or IND, application by the U.S. Food and Drug Administration for its T-cell product candidate, KYV-

WSJ09:30 ET

Express News | Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

Benzinga08:56 ET

Express News | Kyverna's Kyv-101 Receives U.S. FDA Ind Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the Kysa-8 Phase 2 Trial

Reuters08:55 ET

Sector Update: Health Care Stocks Decrease Late Afternoon

Health care stocks were softer late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) edging down 0.1%. The iShares Biotechnology ETF (IBB)

MT NewswiresJun 14 16:00 ET

Sector Update: Health Care

Health care stocks were softer late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) edging down 0.1%. The iShares Biotechnology ETF (IBB)

MT NewswiresJun 14 15:33 ET

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for

BenzingaJun 14 14:13 ET